Jiang Zhu1, Yu Yang, Lin Zhou, Ming Jiang, Mei Hou. 1. Department of Thoracic Oncology, Cancer Center, West China hospital, Sichuan University, Chengdu, 610041, China.
Abstract
BACKGROUND: About 80% of patients with GIST would experience tumor recurrence or metastasis after radical resection. The most common site of the metastasis is the liver. Imatinib mesylate has been proved effective for advanced GIST. The present study was designed to further observe the effectiveness of the imatinib mesylate treatment on the recurrent GIST and the correlation between the liver metastasis and the outcome. METHODS: Forty-two patients who had recurrent GIST after the first radical resection were enrolled. According to the recurrent sites, the patients were divided into 3 groups: group LG (recurrent liver GISTs), group AG (recurrent abdominal GISTs) and group ALG (recurrent abdominal and liver GISTs). All the patients were given imatinib mesylate at an initial dose of 400 mg per day. Their clinical data was prospectively collected. A follow-up over 3 years was conducted. Tumor response, time to progression and survival were evaluated. RESULTS: The long-term imatinib mesylate treatment was safe and well tolerated. At a median follow-up time for 39.5 months, the 3-year survival rate was 66.7%. Median TTP and OS were 37 months (95% CI: 28.2 approximately 45.8 months) and 48 months (95% CI: 37.0 approximately 58.9 months), respectively. There was no statistical difference in tumor response among the 3 groups. The similar TTP (P = 0.291) and OS (P = 0.160) were observed in the 3 groups. CONCLUSIONS: The imatinib mesylate treatment could prolong the survival of the patients who have recurrent GIST after the radical surgery in spite of an existence of the liver metastasis. Survival was not significantly affected by liver metastasis when imatinib mesylate was warranted.
BACKGROUND: About 80% of patients with GIST would experience tumor recurrence or metastasis after radical resection. The most common site of the metastasis is the liver. Imatinib mesylate has been proved effective for advanced GIST. The present study was designed to further observe the effectiveness of the imatinib mesylate treatment on the recurrent GIST and the correlation between the liver metastasis and the outcome. METHODS: Forty-two patients who had recurrent GIST after the first radical resection were enrolled. According to the recurrent sites, the patients were divided into 3 groups: group LG (recurrent liver GISTs), group AG (recurrent abdominal GISTs) and group ALG (recurrent abdominal and liver GISTs). All the patients were given imatinib mesylate at an initial dose of 400 mg per day. Their clinical data was prospectively collected. A follow-up over 3 years was conducted. Tumor response, time to progression and survival were evaluated. RESULTS: The long-term imatinib mesylate treatment was safe and well tolerated. At a median follow-up time for 39.5 months, the 3-year survival rate was 66.7%. Median TTP and OS were 37 months (95% CI: 28.2 approximately 45.8 months) and 48 months (95% CI: 37.0 approximately 58.9 months), respectively. There was no statistical difference in tumor response among the 3 groups. The similar TTP (P = 0.291) and OS (P = 0.160) were observed in the 3 groups. CONCLUSIONS: The imatinib mesylate treatment could prolong the survival of the patients who have recurrent GIST after the radical surgery in spite of an existence of the liver metastasis. Survival was not significantly affected by liver metastasis when imatinib mesylate was warranted.
Authors: H Joensuu; P J Roberts; M Sarlomo-Rikala; L C Andersson; P Tervahartiala; D Tuveson; S Silberman; R Capdeville; S Dimitrijevic; B Druker; G D Demetri Journal: N Engl J Med Date: 2001-04-05 Impact factor: 91.245
Authors: J A Crosby; C N Catton; A Davis; J Couture; B O'Sullivan; R Kandel; C J Swallow Journal: Ann Surg Oncol Date: 2001 Jan-Feb Impact factor: 5.344
Authors: Won Hyuk Choi; Sungsoo Kim; Woo Jin Hyung; Jeong Sik Yu; Chan Il Park; Seung Ho Choi; Sung Hoon Noh Journal: Yonsei Med J Date: 2009-06-23 Impact factor: 2.759
Authors: George D Demetri; Margaret von Mehren; Charles D Blanke; Annick D Van den Abbeele; Burton Eisenberg; Peter J Roberts; Michael C Heinrich; David A Tuveson; Samuel Singer; Milos Janicek; Jonathan A Fletcher; Stuart G Silverman; Sandra L Silberman; Renaud Capdeville; Beate Kiese; Bin Peng; Sasa Dimitrijevic; Brian J Druker; Christopher Corless; Christopher D M Fletcher; Heikki Joensuu Journal: N Engl J Med Date: 2002-08-15 Impact factor: 91.245
Authors: Anthony Paul Conley; Annie Guerin; Medha Sasane; Genevieve Gauthier; Frances Schwiep; Christopher Hunt Keir; Eric Q Wu Journal: J Gastrointest Cancer Date: 2014-12
Authors: Ryan S Turley; Peter D Peng; Srinevas K Reddy; Andrew S Barbas; David A Geller; J Wallis Marsh; Allan Tsung; Timothy M Pawlik; Bryan M Clary Journal: Cancer Date: 2011-11-15 Impact factor: 6.860
Authors: In Sun Yoon; Ji Hoon Shin; Kichang Han; Pyo Nyun Kim; Ki Hun Kim; Yoon-Koo Kang; Heung Kyu Ko Journal: Korean J Radiol Date: 2018-01-02 Impact factor: 3.500
Authors: Deborah van de Wal; Mai Elie; Axel Le Cesne; Elena Fumagalli; Dide den Hollander; Robin L Jones; Gloria Marquina; Neeltje Steeghs; Winette T A van der Graaf; Olga Husson Journal: Cancers (Basel) Date: 2022-04-05 Impact factor: 6.639
Authors: Piotr Rutkowski; Jolanta Andrzejuk; Elżbieta Bylina; Czesław Osuch; Tomasz Switaj; Anna Jerzak vel Dobosz; Urszula Grzesiakowska; Monika Jurkowska; Agnieszka Woźniak; Janusz Limon; Maria Dębiec-Rychter; Janusz A Siedlecki Journal: Med Oncol Date: 2013-11-12 Impact factor: 3.064